Cargando…

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma

BACKGROUND: Outcome in multiple myeloma (MM) has improved substantially over recent years as a result of the availability of multiple novel agents with acceptable safety profile. STUDY DESIGN: Prospective observational study at a tertiary care institute. METHODS: Twenty-five newly diagnosed patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hassan Zafar, Mir Sadaqat, Khan, Afaq Ahmed, Aggarwal, Shyam, Bhargava, Manorama
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	ORIGINAL ARTICLE: Leukemia, Lymphoma & Plasma Cell Disorder
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865101/ https://www.ncbi.nlm.nih.gov/pubmed/29600238 http://dx.doi.org/10.4103/sajc.sajc_59_17

Ejemplares similares

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence
por: Holler, Maximilian, et al.
Publicado: (2022)

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
por: Schavgoulidze, Anaïs, et al.
Publicado: (2022)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
por: Capra, Marcelo, et al.
Publicado: (2021)

Diffuse large B-cell lymphoma: An institutional analysis
por: Gogia, Ajay, et al.
Publicado: (2018)

Adult Burkitt lymphoma: An institutional experience with a uniform chemotherapy protocol
por: Patekar, Mukesh, et al.
Publicado: (2018)

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
por: Sonneveld, Pieter, et al.
Publicado: (2020)

Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
por: Richardson, Paul G., et al.
Publicado: (2020)

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
por: Moreau, Philippe, et al.
Publicado: (2020)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
por: Fazio, Francesca, et al.
Publicado: (2022)

Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
por: Puertas, Borja, et al.
Publicado: (2023)

Regulation of human T-cell leukemia virus type 1 antisense promoter by myocyte enhancer factor-2C in the context of adult T-cell leukemia and lymphoma
por: Madugula, Kiran K., et al.
Publicado: (2022)

IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma
por: Pisano, Michael D., et al.
Publicado: (2023)

Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment
por: Soncini, Debora, et al.
Publicado: (2021)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy
por: Sheu, Tommy, et al.
Publicado: (2018)

Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way
por: Giannandrea, Domenica, et al.
Publicado: (2022)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
por: Moore, Kari Lenita Falck, et al.
Publicado: (2022)

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities
por: Giesen, Nicola, et al.
Publicado: (2022)

Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
por: Biran, Noa, et al.
Publicado: (2021)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis
por: Mangiacavalli, Silvia, et al.
Publicado: (2022)

Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins
por: Taiana, Elisa, et al.
Publicado: (2022)

Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs
por: Takamatsu, Hiroyuki, et al.
Publicado: (2023)

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
por: Talbot, Alexis, et al.
Publicado: (2023)

High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex
por: Zhou, Xiang, et al.
Publicado: (2023)

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial
por: Richardson, Paul G., et al.
Publicado: (2023)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
por: Leleu, Xavier, et al.
Publicado: (2022)

Obesity and the Risk for a Hematological Malignancy: Leukemia, Lymphoma, or Myeloma
por: Lichtman, Marshall A.
Publicado: (2010)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2020)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial
por: Spencer, Andrew, et al.
Publicado: (2022)

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years
por: Yokoyama, Akihiro, et al.
Publicado: (2022)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling
por: Lawless, Sarah, et al.
Publicado: (2022)

IgM monoclonal gammopathy of undetermined significance: clinicopathologic features with and without IgM-related disorders
por: Bruehl, Frido K., et al.
Publicado: (2023)

Amyloidogenic light chains impair plasma cell survival
por: Pick, Marjorie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_scm6u22ekae1cjf1vuokrpsp3b